Neuberger Berman Group’s Corcept Therapeutics CORT Stock Holding History

Neuberger Berman Group’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$886K	Buy	10,194 +3,299	+48%	+$199K	﹤0.01%	1573
2026 Q1	$278K	Sell	6,895 -175,069	-96%	-$6.55M	﹤0.01%	1866
2025 Q4	$6.33M	Buy	181,964 +131,771	+263%	+$10.3M	﹤0.01%	919
2025 Q3	$4.17M	Sell	50,193 -14,686	-23%	-$1.06M	﹤0.01%	1006
2025 Q2	$4.76M	Buy	64,879 +8,959	+16%	+$650K	﹤0.01%	974
2025 Q1	$6.39M	Sell	55,920 -72,749	-57%	-$4.43M	0.01%	883
2024 Q4	$6.48M	Buy	128,669 +12,332	+11%	+$646K	0.01%	896
2024 Q3	$5.38M	Buy	+116,337	New	+$4.13M	﹤0.01%	929
2017 Q4	–	Sell	-39,891	Closed	-$770K	–	1764
2017 Q3	$770K	Sell	39,891 -3,249	-8%	-$48.4K	﹤0.01%	1212
2017 Q2	$509K	Sell	43,140 -78,706	-65%	-$855K	﹤0.01%	1311
2017 Q1	$1.33M	Buy	121,846 +22,454	+23%	+$197K	﹤0.01%	1084
2016 Q4	$722K	Buy	+99,392	New	+$779K	﹤0.01%	1206

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Neuberger Berman Group's CORT Position: Q2 2026 in Review

Neuberger Berman Group increased its Corcept Therapeutics (CORT) stake by 48% in Q2 2026, buying an estimated $199K and bringing the position to 10,194 shares worth $886K. The position accounts for ﹤0.01% of the portfolio, ranked #1573.

Neuberger Berman Group first reported a position in CORT in Q4 2016 and has held it in 12 quarters since. The position peaked at $6.48M in Q4 2024. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Neuberger Berman Group held 10,194 shares of Corcept Therapeutics worth $886K as of Q2 2026.
Neuberger Berman Group bought 3,299 Corcept Therapeutics shares in Q2 2026, an estimated $199K.
Corcept Therapeutics made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #1573 holding.
Neuberger Berman Group first reported a position in Corcept Therapeutics in Q4 2016 and has held it in 12 quarters since.
Neuberger Berman Group's Corcept Therapeutics position peaked at $6.48M in Q4 2024.
422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.